ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Chemomab Therapeutics Ltd

Chemomab Therapeutics Ltd (CMMB)

1.42
0.19
(14.98%)
Closed July 24 4:00PM
1.156
-0.264
( -18.59% )
Pre Market: 9:25AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.156
Bid
1.15
Ask
1.19
Volume
1,277,386
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.42
Open
-
Last Trade Time
09:25:54
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
14,204,735
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Chemomab Therapeutics Ltd

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlyi... Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Tel Aviv, Center, Isr
Founded
1970
Chemomab Therapeutics Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CMMB. The last closing price for Chemomab Therapeutics was $1.42. Over the last year, Chemomab Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

Chemomab Therapeutics currently has 14,204,735 shares outstanding. The market capitalization of Chemomab Therapeutics is $20.17 million.

CMMB Latest News

Chemomab Therapeutics Announces $10 Million Private Placement

TEL AVIV, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative...

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic...

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab’s...

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation—...

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.148
(0.00%)
1.58M
AADRAdvisorShares Dorsey Wright ADR ETF
$ 61.52
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.57
(0.00%)
108
AACIArmada Acquisition Corporation I
$ 11.35
(0.00%)
200
AACGATA Creativity Global
$ 0.68
(0.00%)
56
AAGRAfrican Agriculture Holdings Inc
$ 0.148
(0.00%)
1.58M
AADRAdvisorShares Dorsey Wright ADR ETF
$ 61.52
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.57
(0.00%)
108
AACIArmada Acquisition Corporation I
$ 11.35
(0.00%)
200
AACGATA Creativity Global
$ 0.68
(0.00%)
56
TIVCTivic Health Systems Inc
$ 0.30599
(0.00%)
41.03M
STSSSharps Technology Inc
$ 0.2373
(0.00%)
34.99M
POAIPredictive Oncology Inc
$ 1.07
(0.00%)
34.11M
PBMPsyence Biomedical Ltd
$ 0.3914
(0.00%)
31.9M
CEROCERo Therapeutics Holdings Inc
$ 0.211
(0.00%)
27.74M

CMMB Discussion

View Posts
TheFinalCD TheFinalCD 2 hours ago
1.20 POP & DROP :/
👍️0
TheFinalCD TheFinalCD 2 hours ago
1.79 to 1.44 that was fast

&dirty
👍️0
TheFinalCD TheFinalCD 3 hours ago
1.45 Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis $CMMB https://t.co/TGwy7dPUTO— Health Stocks News (@health_stocks) July 25, 2024
👍️0
glenn1919 glenn1919 22 hours ago
CMMB.........................https://stockcharts.com/h-sc/ui?s=CMMB&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 days ago
CMMB under $2
👍️0
TheFinalCD TheFinalCD 5 months ago
$MEDS $13 HALTED UP AGAIN, MAY TEST $17 HIGH SOON
👍️0
tw0122 tw0122 5 months ago
MEDS $16 lol some more .. CMMB AMBO ZKIN MEDS 16.65 +302.17% 3.19M
AgriFORCE Growing .AGRI
0.7222 +237.48% 35.78M
Shineco IncSISI
3.10 +110.17% 5.5M
Tevogen Bio Holdin.TVGN
8.10 +77.63% 0.43K
Fusion Fuel GreenHTOOW
0.56 +60.00% 1.11K
Chemomab Therapeut.CMMB
0.93 +47.97% 997.87K
D Wave Quantum IncQBTS
2.31 +33.53% 3.18M
ZK InternationalZKIN
1.00 +31.58% 2.73K
Kintara Therapeuti.KTRA
0.1239 +26.43% 36.64M
Ambow EducationAMBO
3.88 +29.33% 0.36K
👍️0
TheFinalCD TheFinalCD 5 months ago
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases $CMMB https://t.co/38E8jz1cIb— Health Stocks News (@health_stocks) February 20, 2024
👍️0
wickerman wickerman 7 months ago
New bagholders getting dumped on lol they never learn.
👍️0
Distantpulse Distantpulse 8 months ago
Looks that way……
👍️0
wickerman wickerman 8 months ago
$CMMB has always been a SCAM...another R/S next.
👍️0
herbied47 herbied47 8 months ago
In for a swing!
👍️0
Distantpulse Distantpulse 8 months ago
Complete Ineptitude……most small cap biotech stocks are scams anyway. Only a select few actually do anything. At least I learned from my mistakes I’ve made in the past. Lol but I sure paid for it.
👍️0
subslover subslover 8 months ago
Company is a front for a paper press
👍️0
Pt3 Pt3 8 months ago
Lucky didn't average down or bag more trap above 1+ lol
👍️0
subslover subslover 8 months ago
Could bounce over $1.00 again today. Forget about this POS tomorrow.
👍️0
Distantpulse Distantpulse 8 months ago
Absolutely! Was just trying to get out of this play at a smaller loss…..
👍️0
subslover subslover 8 months ago
Remember once a dog always a dog. Thousands of other stocks to play ")
👍️0
Distantpulse Distantpulse 8 months ago
Really really frustrating…….
👍️0
subslover subslover 8 months ago
Same dog but different fleas
👍️0
Distantpulse Distantpulse 8 months ago
Yep……
👍️0
wickerman wickerman 8 months ago
$CMMB great escape hatch for bagholders before the next R/S.

They always dilute extra hard into their own news.
👍️0
Distantpulse Distantpulse 8 months ago
And it can’t even stay above a $1 smfh.
👍️0
subslover subslover 8 months ago
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
—CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition—

—CM-101's Phase 2 SPRING Trial in PSC is Advancing Towards Completion of Enrollment with Top-line Readout Expected in 2H 2024—

TEL AVIV, Israel, Nov. 15, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted CM-101 Fast Track designation for the treatment in adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease that can result in liver transplant, cancer and early death.


Fast Track is a process developed by the FDA to facilitate and expedite the development of new treatments that demonstrate a potential to address unmet medical needs in serious or life-threatening conditions. Programs with Fast Track designation can benefit from early and more frequent interactions with the FDA during the clinical development process. Therapeutic candidates with Fast Track designation may also be eligible for priority review and accelerated approval if supported by clinical data.

"This FDA Fast Track designation is an important validation of CM-101's potential to have a major impact on this devastating disease that attacks people in their prime years and lacks any approved treatments," said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. "We designed the CM-101 Phase 2 SPRING trial to be supportive of a registrational trial in patients with PSC, and we welcome the enhanced opportunities for working closely with the FDA and for acceleration of the development and review process provided by Fast Track status."

There are no FDA-approved treatments for PSC. CM-101 is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, which in preclinical and clinical studies has been associated with key pathways underlying PSC pathophysiology. CM-101's dual anti-inflammatory and anti-fibrotic activity, which is designed to break the vicious cycle driving these pathways, has demonstrated the potential for disease modifying activity in preclinical and early clinical studies of PSC-related processes.

Chemomab Chief Medical Officer Matt Frankel, MD, added, "Promising biomarker and elastography results from our Phase 2a liver fibrosis study in nonalcoholic steatohepatitis (NASH) patients reported earlier this year reinforced our optimism about the therapeutic potential of CM-101. There are common fibrosis pathways in NASH and PSC, and CM-101's relevance to PSC is supported by extensive preclinical and patient sample studies. We also are encouraged by robust patient enrollment in the SPRING trial, which speaks to the high unmet need experienced by these patients. We look forward to continuing our work with PSC patients, their clinicians and the FDA to expedite advancement of CM-101 as a potential treatment for this terrible disease."

Chemomab's Phase 2 SPRING trial (NCT04595825) is a double-blind, placebo-controlled study assessing the safety and tolerability of CM-101 in PSC patients. The trial is also measuring a wide range of relevant biomarkers and physiological parameters. Patient enrollment in the trial is advancing towards completion and Chemomab anticipates reporting a top-line readout in the second half of 2024.

About CM-101
CM-101 is a monoclonal antibody that neutralizes CCL24, a soluble protein that helps drive the inflammatory and fibrotic pathways central to many fibro-inflammatory diseases. CCL24's role as a therapeutic target has been validated in extensive preclinical studies and Chemomab researchers have demonstrated preclinical proof-of-concept for CM-101 in multiple animal and patient sample studies. CM-101 was safe and well tolerated in Phase 1 and Phase 2 clinical trials to date. In a Phase 1b study it improved liver biomarkers, decreased liver stiffness and demonstrated a favorable PK and target engagement profile in patients with nonalcoholic fatty liver disease (NAFLD). Data from a completed Phase 2a liver fibrosis trial in NASH patients (NCT05824156) reported earlier this year showed consistent, positive improvements in key inflammatory and fibrogenesis-related biomarkers, including several that may serve as a potential bridge to activity in PSC. CM-101 has Orphan Drug designation from the FDA and Europe's EMA and is currently being evaluated in PSC patients in the Phase 2 SPRING trial.

About Primary Sclerosing Cholangitis
PSC is a rare, progressive liver disease, characterized by inflammation and fibrosis (scarring) of the bile ducts. Eventually, it can lead to cirrhosis of the liver and liver failure. PSC also increases the risk of various cancers, which account for about half of PSC deaths. PSC affects an estimated 30,000 patients in the U.S. and about 80,000 worldwide. The disease can occur in all ages, genders and races, but is more common in men and is typically diagnosed in patients in their 40s. The underlying cause of PSC is unknown, but about 75% of individuals with PSC also have inflammatory bowel disease. Currently there are no FDA or EMA-approved therapies for patients with PSC. Liver transplant is common in advanced cases, but even then, PSC re-occurs in about 20% of transplanted patients. There is a high unmet need for therapeutic options to address the symptoms and modify the progression of this devastating illness.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the length, duration and impact of the war in Israel on Chemomab's business and operations; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including those found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from three clinical trials of CM-101 in patients, including a Phase 1b trial in NAFLD patients, a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. The CM-101 program for the treatment of systemic sclerosis is Phase 2-ready and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with top-line data expected in the second half of 2024. For more information about Chemomab, visit chemomab.com.

Contacts:

Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic CommunicationsPhone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com



https://c212.net/c/img/favicon.png?sn=LA69540&sd=2023-11-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-receives-fda-fast-track-designation-for-cm-101-for-the-treatment-of-primary-sclerosing-cholangitis-301988732.html

SOURCE Chemomab Therapeutics, Ltd.

Back to News Headlines
👍️0
Distantpulse Distantpulse 10 months ago
Here we f’in go…..below a $1. Smfh.
👍️0
Distantpulse Distantpulse 11 months ago
Wouldn’t surprise me…..100% loss incoming. Smfh!
👍️0
wickerman wickerman 12 months ago
$CMMB under $1 then another reverse split to dilute.
👍️0
Distantpulse Distantpulse 1 year ago
Lol for real!
👍️0
subslover subslover 1 year ago
Its a dog with fleas! lol
👍️0
Distantpulse Distantpulse 1 year ago
And it still crashes…….smfh.
👍️0
subslover subslover 1 year ago
NEWS
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
-Treatment with CM-101 Improves Additional Biomarkers of Fibrosis and Inflammation,
`Reinforcing and Extending Initial Study Results-

-Provides New Insights into CM-101 Activity in NASH Patients at Greater Risk of Progressive Disease, Providing Further Support for CM-101's Direct Anti-inflammatory and Anti-fibrotic Dual Mode of Action-

-Demonstrates Improvements in Key Biomarkers Associated with Other Fibrotic Liver Diseases
Including Primary Sclerosing Cholangitis-

TEL AVIV, Israel, June 21, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported topline results from secondary analyses of its Phase 2a liver fibrosis trial assessing CM-101, its first-in-class CCL24-neutralizing antibody, in patients with non-alcoholic steatohepatitis (NASH). The results were included in a late-breaking poster presentation at the 2023 EASL Congress in Vienna, Austria.1


Overall, the data showed improvements across an additional set of inflammatory and fibrotic biomarkers that are consistent with the positive clinical results Chemomab released in January. Additionally, in NASH patients at greater risk of disease progression, CM-101 treatment resulted in a greater biomarker response than in NASH patients with lower risk disease or in placebo-treated patients.

Adi Mor, PhD, Chemomab co-founder, CEO and CSO, commented, "These additional analyses of our liver fibrosis data in NASH patients are very encouraging. They supplement and extend our initial data results, showing a consistent pattern of improvement in CM-101-treated patients in biomarkers associated with fibrogenesis and inflammation. We are especially pleased to see that CM-101 treated-patients with higher FAST scores—those at greater risk of progressive disease—tended to demonstrate greater biomarker improvements than those with lower FAST scores. Additionally, we consider these data to be highly relevant to our ongoing CM-101 Phase 2 trial in primary sclerosing cholangitis (PSC), demonstrating improvements in biomarkers that are also associated with the inflammation and fibrogenesis found in PSC patients. Notably, our PSC trial involves the evaluation of significantly higher doses of CM-101, with patient dose cohorts of 10mg/kg and 20mg/kg administered intravenously, compared to the liver fibrosis study in NASH patients, which used a subcutaneous dose of 5mg/kg."

The new analyses assessed additional biomarkers and also used the FibroScan-AST (FAST) score to categorize study patients based on progressive disease risk, thereby enabling the evaluation of CM-101 activity in the main target population of patients with more active disease.2 FAST is a validated score composed of non-invasive FibroScan® and AST measurements that is used to identify patients with a high risk of NASH progression.3 The results showed that:

FAST scores were improved in a higher proportion of CM-101-treated patients than in placebo patients.
CM-101-treated patients with higher FAST scores demonstrated greater improvements in key fibro-inflammatory biomarkers, such as Pro-C3, than patients with lower FAST scores or placebo patients.
CM-101-treated patients with higher FAST scores showed improvements in several fibro-inflammatory biomarkers generally comparable to those achieved in several recent successful NASH clinical trials.
In these secondary analyses, CM-101-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation:

FIB-4, an index for determining NASH status that includes age, platelet count, AST and ALT levels, was improved in CM-101-treated patients vs. placebo patients.
AST/ALT ratio, a liver enzyme ratio, was improved in CM-101-treated patients vs. placebo patients.
Neutrophil-to-Lymphocyte Ratio (NLR), an indicator of inflammation, was improved in CM-101-treated patients vs. placebo patients, and NLR was further improved in groups with higher FAST scores.
PRO-C3, which captures active fibrogenesis and correlates with fibrotic disease severity, was improved in CM-101-treated patients vs. placebo patients and was further improved in groups with higher FAST scores. As an overall indicator of fibrogenesis and fibrotic disease, PRO-C3 is also considered a "bridge" to PSC and other anti-fibrotic indications.
Scott L. Friedman, MD, Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York City, is an expert on the fibrosis associated with chronic liver disease and a co-author of the EASL poster. Dr. Friedman noted, "It is encouraging that consistent positive improvements are seen across a range of fibro-inflammatory biomarkers in both CM-101 Phase 2a study analyses. The greater improvement in biomarkers in the higher FAST score-enriched subgroup provides further evidence of CM-101's potential to have a positive impact on fibrotic diseases such as NASH and PSC, whose pathophysiology may be associated with the dual fibro-inflammatory mechanism that CM-101 is intended to address."

In January, the company reported that the Phase 2a liver fibrosis trial met its primary endpoint of safety and tolerability and that CM-101 achieved reductions in secondary endpoints that included a range of liver fibrosis biomarkers and physiologic assessments. The EASL poster also summarized these results, including:

CM-101 treatment demonstrated a favorable PK-target engagement profile.
CM-101 treatment was associated with improvements in multiple fibrosis biomarkers and with a reduction in FibroScan liver stiffness stage.
CM-101 treatment was associated with improvements in more than one liver fibrosis-related biomarker—almost 60% of CM-101 patients responded in at least three biomarkers, compared to no placebo patients.
Higher levels at baseline of CM-101's target—the soluble chemokine CCL24—in CM-101-treated patients were associated with greater reductions in fibrosis-related biomarkers and a greater likelihood of being a multiple biomarker responder.
About the Phase 2 Liver Fibrosis Trial in NASH Patients
The randomized, placebo-controlled trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 (14 patients) or placebo (9 patients). Patients received eight doses of 5 mg/kg of CM-101 or placebo, administered by subcutaneous (SC) injection once every two weeks, for a treatment period of 16 weeks. This trial was primarily designed to assess the safety and tolerability of the SC formulation of CM-101 and to evaluate the drug's impact on liver fibrosis biomarkers relevant to both NASH and other rare fibro-inflammatory conditions that are the focus for the company, such as primary sclerosing cholangitis. For more information on the initial trial results, click here.

Poster presentation: Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: A proof- of-concept study June 21-24, 2023, 9-17:00 CEST every day: Poster-Late-Breaker, LBP-28
NASH patients at risk for disease progression defined as FAST scores NAS≥4; F≥2.
Woreta TA, Van Natta ML, Lazo M, Krishnan A, Neuschwander-Tetri BA, Loomba R, et al. (2022) Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE 17(4): e0266859.
About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. To date, Chemomab has reported encouraging results from three clinical trials, including a Phase 2 liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with topline data expected in the latter part of 2024. For more information on Chemomab, visit chemomab.com.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including those found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Contacts:


Investors:

Investors & Media:

Irina Koffler

Barbara Lindheim

LifeSci Advisors, LLC

Chemomab Therapeutics

Phone: +1 (917) 734-7387

Consulting Vice President, Investor & Public Relations

ir@chemomab.com

Strategic Communications


barbara.lindheim@chemomab.com
👍️0
huka huka 1 year ago
Doubled 1.42
👍️0
Distantpulse Distantpulse 1 year ago
POFS! New all time lows……
👍️0
huka huka 1 year ago
Took a 1.82 starter premarket GAMBLE
👍️0
Distantpulse Distantpulse 1 year ago
Nvm, just saw there was an offering. Smfh. Ughhhh!
👍️0
Distantpulse Distantpulse 1 year ago
Again this stock makes zero sense to me. 11 mil float and it can’t hold any gains?!? Is it that shorted? Wtf.
👍️0
glenn1919 glenn1919 1 year ago
CMMB..............................https://stockcharts.com/h-sc/ui?s=CMMB&p=W&b=5&g=0&id=p86431144783
👍️0
wickerman wickerman 2 years ago
$CMMB just the old bagholders dumping onto new ones.
This is a zero of a company with zero catalysts.
👍️0
Distantpulse Distantpulse 2 years ago
I sure hope so! Lol
👍️0
ZZZ888 ZZZ888 2 years ago
Probably just people try to dump their shares that they’ve had for a while I bought more want when it dropped down today. We will have our day when everything is approved or if they get bought out
👍️0
Distantpulse Distantpulse 2 years ago
Great news and this POS can’t even hold the prior days high…….unbelievable.
👍️0
Distantpulse Distantpulse 2 years ago
I’m scared to death to avg down on any penny plays these days. No one is investing now. I just got burned on a couple that fell bad and did R/S!! Lost a lot! I don’t want to do that here……
👍️0
ZZZ888 ZZZ888 2 years ago
I don’t even know anymore do you buy more of this and average down some more whole market is out of control
👍️0
Distantpulse Distantpulse 2 years ago
Sub 1………incoming
👍️0
Distantpulse Distantpulse 2 years ago
New all time lows……..smfh!
👍️0
ZZZ888 ZZZ888 2 years ago
I’m in around 6. Feel the same. Going into the force was a nice sign just need to hold it then a catalyst would be very nice
👍️0
Distantpulse Distantpulse 2 years ago
I’d much rather it hit my avg of $8.50 trust me. Lol with the low float, it’s possible with a catalyst……
👍️0
ZZZ888 ZZZ888 2 years ago
You tell me. You sub 1.
👍️0
Distantpulse Distantpulse 2 years ago
What’s the catalyst?
👍️0
ZZZ888 ZZZ888 2 years ago
How’s that sub dollar looking?
👍️0

Your Recent History

Delayed Upgrade Clock